Skip to content

Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma

Oct 2026 · Thyroid · Vol 36, pp. 1275 - 1280 · 0 citations · 22 references
Medicine

Abstract

Background: Selpercatinib is approved for RET-mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic progression, selpercatinib was started urgently, off-label, before molecular testing results were available. She had rapid clinical improvement, marked calcitonin and CEA decline, and a remarkable and durable radiographic partial response until the last follow-up (29 months). Summary: Repeated germline and tumor testing [RET Sanger sequencing, germline whole-exome sequencing, tumor DNA/RNA panel testing, RET Multiplex Ligation-Dependent Probe Amplification (MLPA), tumor whole-genome sequencing] identified no pathogenic or actionable RET variant, indel, copy-number alteration, or fusion. The only somatic alterations found were HRAS p.G13S and truncating NF1 p.R2450*. Conclusions: This remarkable response to selpercatinib in apparently RET-negative MTC is hypothesis generating and requires confirmation. HRAS/NF1 co-alteration supports RAS/MAPK activation but does not explain sensitivity to selective RET inhibition.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.